linjc16/ctgov huggingface dataset:
Liver Regeneration

Study Overview
=================
Brief Summary
-----------------
The liver is the only visceral organ with a tremendous capacity to regenerate. We don't yet understand how normal liver regeneration occurs (on a molecular level) or how to distinguish between normal and abnormal/neoplastic regeneration. This study will characterize the role of the different liver cell types in the regeneration process and will examine gene expression changes in the various liver cell types.

Detailed Description
-----------------
New studies are demonstrating that rodent models of the liver and liver disease are inadequate. The human liver is quite different and needs to be studied directly. The cell expression of human liver cells during regeneration has many implications for treatment of patients with cirrhosis and cancer. This study will characterize the role of the different liver cell types in the regeneration process and will examine gene expression changes in the various liver cell types. We hypothesize that there is significant crosstalk among hepatocytes, macrophages, and T-cell subsets in the human liver, stimulating the regenerative process. Tissue will be obtained from serial biopsies of healthy liver that is regenerating in patients who undergo liver resection for metastatic colorectal cancer. All participants must first provide written informed consent and meet study eligibility criteria. The first tissue sample will be collected intraoperatively, then serial fine-needle aspiration biopsies (FNAB) will be performed approx. 1 week following surgery, and 1 month following surgery. Liver regeneration will also be assessed using routine imaging of the liver at approx. 3 months. Retrospective (previously collected diagnostic or biobanked) tissue is also being included for study, given lower than anticipated enrollment.

Official Title
-----------------
Understanding the Molecular Basis of Normal Liver Regeneration

Conditions
-----------------
Liver Diseases, Liver Cancer

Intervention / Treatment
-----------------
* Procedure: Liver Biopsy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: willing and able to provide written informed consent No history of liver disease or dysfunction Exclusion Criteria: Patients who receive chemotherapy within the 6 weeks prior to their hepatectomy and/or would be started on active chemotherapy within the first 4 weeks post-hepatectomy. Patients requiring long-term anticoagulation

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Procedure: Liver Biopsy|liver tissue will be collected via core biopsy during liver resection surgery and post-operatively by fine needle aspiration biosy|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Gene expression | gene expression | week 1 post-resection |
Operator Radiation Protection During Cardiac Catheterization Using Mavig X-ray Protective Drapes®.

Study Overview
=================
Brief Summary
-----------------
Interventional cardiologists are exposed to significant doses of scatter radiation during cardiac catheterization and percutaneous coronary intervention. Traditional methods of reducing the radiation dose for operators in the cardiac catheterization laboratory include limiting the use of radiation, radiation protection aprons and shields, and the use of lead eye glasses. Despite these measures several parts of the operators body, including the head and neck, are poorly screened from scatter radiation. Radiation protection drapes have been developed for use in cardiac catheterization but no randomized controlled study has yet been performed with the commercially available Mavig X-ray Protective Drapes®. The aim of this study is to evaluate operator radiation protection using Mavig X-ray Protective Drapes®.

Official Title
-----------------
Operator Radiation Protection During Cardiac Catheterization Using Mavig X-ray Protective Drapes®.

Conditions
-----------------
Radiation Exposure

Intervention / Treatment
-----------------
* Other: Mavig X-ray Protective Drapes


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patient undergoing the procedure is older than 18 years and is planned for a coronary angiogram, cardiac catheterization and/or percutaneous coronary intervention. The coronary angiogram/cardiac catheterization/PCI procedure is elective. The patient undergoing the procedure is male, or if female, has no childbearing potential or is not pregnant. Exclusion Criteria: 1. The procedure is an emergency and/or the patient is unstable. -

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Study<br> | Other: Mavig X-ray Protective Drapes<br>* Mavig X-ray Protective Drapes®<br>|
| No Intervention: Control<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Operator radiation dose | Gray | Immediate |
Prevalence of Inadvertent Hyperventilation During Intraoperative Anesthetic Care

Study Overview
=================
Brief Summary
-----------------
This is a retrospective chart review of patients undergoing spinal fusion surgery to see the prevalence of hyperventilation.

Detailed Description
-----------------
Retrospective review of the operative schedules to identify patients who have undergone spinal fusion with placement of an arterial cannula for intermittent arterial blood gas analysis. The intraoperative records will be retrospectively reviewed. The following demographic data will be recorded: age, weight, gender, and co-morbid medical conditions. Ventilatory parameters at the time of ABG analysis will include (respiratory rate and tidal volume). ABG data will be collected.

Official Title
-----------------
Prevalence of Inadvertent Hyperventilation During Intraoperative Anesthetic Care

Conditions
-----------------
Spinal Fusion

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients who underwent complex surgical procedures (spinal fusions) which necessitated arterial line placement and intermittent arterial blood gas analysis Exclusion Criteria: None
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Spinal fusion<br>Patients who underwent complex surgical procedures (spinal fusions) which necessitated arterial line placement and intermittent arterial blood gas analysis | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Incidence of inadvertent hyperventilation |  | Day 1 |
Analysis of B Cells From Autoimmune Individuals

Study Overview
=================
Brief Summary
-----------------
This observational study aims at finding out if individual with autoimmunity exhibit increased numbers of B cells that express two types (instead of one type) of antibodies, and if B cells of individuals genetically susceptible to autoimmunity display defects in the biological process of tolerance, which removes B cells that participate in autoimmunity.

Detailed Description
-----------------
Peripheral blood B cells of SLE patients are analyzed by flow cytometry to determine the frequency of B cells co-expressing immunoglobulin kappa an lambda light chains. This frequency is correlated to the disease activity.

Official Title
-----------------
Analysis of B Cells From Autoimmune Individuals

Conditions
-----------------
Lupus Erythematosus, Rheumatoid Arthritis, Type 1 Diabetes

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Adult Males and Females diagnosed with Lupus; Adult Females who are pregnant and diagnosed with: lupus erythematosus rheumatoid arthritis, or type 1 diabetes. Exclusion Criteria: Adult males or adult females treated with B-cell depletion therapies.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Frequency of kappa to lambda ratios of B cells in blood of autoimmune adults | For peripheral adult blood, the main outcome measure is the frequency of κ/λ (kappa to lambda ratios) dual immunoglobulin B cells within the overall B (CD19+ or CD20+) cell population. The collected data will be aggregated as the average frequency of κ/λ B cells in subjects with autoimmunity relative to healthy controls. | 1 day | 
| Frequency of CD19 and IgM low B cells in cord blood of babies born from autoimmune mothers | For cord blood samples, the main outcome measurement is the frequency of B cells that express both low levels of CD19 and IgM within the total (CD19+ or CD20+) B cell population. The collected data will be aggregated as the average frequency of CD19low/IgMlow B cells in subjects that were born from autoimmune mothers relative to those born from healthy mothers. Moreover, data will also be stratified in respect to the presence or absence of the PTPN22-R620W allele, which is a risk allele for autoimmunity. | 1 day |
Effect of Physical Therapy Exercise Program and Low-Level Laser Therapy on the Treatment of Cervicogenic Somatosensory Tinnitus

Study Overview
=================
Brief Summary
-----------------
To determine the effectiveness of adding a physical therapy exercise program to low-level laser therapy on the treatment of chronic tinnitus treatment

Official Title
-----------------
Effect of Adding Supervised Physical Therapy Exercise Program to Photobiomodulation Therapy in the Treatment of Cervicogenic Somatosensory Tinnitus: A Randomized Controlled Study

Conditions
-----------------
Tinnitus, Subjective

Intervention / Treatment
-----------------
* Other: Exercise Therapy program added to laser therapy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age ranged from 45 to 55 years old both sex Unilateral tinnitus Stable tinnitus for at least 3 months suffering from severe chronic non-fluctuating subjective cervicogenic somatic tinnitus (CST) Exclusion Criteria: tinnitus with clear ontological etiologies as perforation of the tympanic membrane external otitis media conductive hearing loss patients with a traumatic cervical spine injury, tumors Any history of exposure to ototoxic drugs/substances psychotic disorders with auditory hallucination

Ages Eligible for Study
-----------------
Minimum Age: 45 Years
Maximum Age: 55 Years


Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Low level LASER Therapy<br>Subjects in this group received low-level laser therapy | Other: Exercise Therapy program added to laser therapy<br>* a supervised physical therapy exercise program for the neck muscles in the form of manual mobilizations for sternocleidomastoid muscle and upper fibers of trapezius in addition to myofascial trigger point release<br>|
| Experimental: Exercise group<br>Subjects in this group received additional planned exercise therapy program | Other: Exercise Therapy program added to laser therapy<br>* a supervised physical therapy exercise program for the neck muscles in the form of manual mobilizations for sternocleidomastoid muscle and upper fibers of trapezius in addition to myofascial trigger point release<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| VAS | Numerical estimates of tinnitus severity before and after treatment for both groups | 8 weeks |
Evaluation of Learning Curve of Manual Skills in Anesthesia Residents

Study Overview
=================
Brief Summary
-----------------
To determine number of cases need to perform in new anesthesia residents to be proficient in manual skills.

Detailed Description
-----------------
Manual skills in anesthesia are complex and unique to learn. The adequate cases need to be done to reach optimal success rate for each procedure is still varied from data available from the publications. This study is designed to evaluate the number of cases need to perform in new anesthesia residents to be proficient in anesthesia skills, which are intubation, laryngeal mask insertion, spinal anesthesia, epidural anesthesia, radial artery cannulation and internal jugular vein cannulation.

Official Title
-----------------
Evaluation of Learning Curve of Manual Skills in Anesthesia Residents

Conditions
-----------------
Intubation Skill, Laryngeal Mask Airway Insertion Skill, Spinal Anesthesia Skill, Epidural Anesthesia Skill, Radial Artery Cannulation Skill, Internal Jugular Vein Cannulation Skill

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: new anesthesia residents Exclusion Criteria: none

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
manual skill, anesthesia residents
Reducing Mesh Infections in Open Hernia Repairs

Study Overview
=================
Brief Summary
-----------------
Soaking meshes in a vancomycin solution just prior to their use in open hernia repairs will decrease rates of mesh infection

Official Title
-----------------
Does Soaking Synthetic Mesh in Vancomycin Solution Reduce Mesh Infections in Open Hernia Repairs?

Conditions
-----------------
Patients Undergoing Open Hernia Repair, Patients Undergoing Ventral or Inguinal Hernia Repair

Intervention / Treatment
-----------------
* Procedure: vancomycin-soaked mesh
* Procedure: plain mesh


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: open ventral or inguinal hernia repair Exclusion Criteria: laparoscopic hernia repair non ventral or inguinal hernia repairs

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: plain mesh<br>standard practice of using plain mesh (non vancomycin-soaked) for open hernia repair | Procedure: plain mesh<br> <br> * Other names: non vancomycin-soaked mesh;|
| Experimental: vancomycin-soaked mesh<br>use of vancomycin-soaked mesh for open hernia repair | Procedure: vancomycin-soaked mesh<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| mesh infections |  | 6 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| hernia recurrence |  | 6 months | 
| postoperative seroma formation |  | 6 months |
Long-Term Outcome of Subjects With Elevated PSA in Healthy Taiwanese Men

Study Overview
=================
Brief Summary
-----------------
To determine the long-term survival outcome of subjects who had various PSA levels at screening

Official Title
-----------------
Long-Term Outcome of Subjects With Elevated PSA in Healthy Taiwanese Men

Conditions
-----------------
Prostate Cancer

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Health men who received PSA screening at NTUH and CGMH Exclusion Criteria: Prior history of prostate cancer

Ages Eligible for Study
-----------------
Minimum Age: 41 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Healthy men<br>Healthy men who received PSA screening | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Diagnosis of prostate cancer |  | 20 years (average) | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Cancer-specific death |  | 20 years (average) | 
| Overall survival |  | 20 years (average) | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
PSA,, asian men,, survival
Vitrectomy and Bevacizumab for Diffuse Diabetic Macular Edema

Study Overview
=================
Brief Summary
-----------------
To Evaluate combined effect of vitrectomy and bevacizumab to stabilize retinal thickness and visual acuity in patients with diffuse diabetic macular edema and their relation to renal disease.

Official Title
-----------------
Pars Plana Vitrectomy and Bevacizumab for the Treatment of Diffuse Diabetic Macular Edema (A Pilot Study)

Conditions
-----------------
* Diffuse Diabetic Macular Edema

Intervention / Treatment
-----------------
* Procedure: Bevacizumab + Pars plana vitrectomy
* Procedure: Bevacizumab + pars plana vitrectomy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Older than 25 yo Diffuse diabetic macular edema with or without previous treatment Exclusion Criteria: Another retinal disease Pregnancy

Ages Eligible for Study
-----------------
Minimum Age: 25 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: 1<br>Renal disease | Procedure: Bevacizumab + Pars plana vitrectomy<br>* 2.5 mg / 0.1 ml bevacizumab after pars plana vitrectomy. Limitorexis would be optional.<br>|
| Active Comparator: 2<br>Without renal disease | Procedure: Bevacizumab + pars plana vitrectomy<br>* 2.5 mg /0.1 ml of bevacizumab after pars plana vitrectomy<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Retinal thickness |  | 3 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Visual acuity |  | 3 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
edema, retinal thickness, diabetic retinopathy
Evaluation of the Effects of Treatment With Bioarginin C in Adult Subjects Belonging to the Post-Covid Day Hospital

Study Overview
=================
Brief Summary
-----------------
Long Covid could be much more frequent than it is thought to be. Few dwell on the great problem represented by the post covid syndrome. The virus often leaves important marks on our body, and those who recover face problems of various kinds: chronic fatigue, shortness of breath, dry cough, headache, cognitive difficulties. On the duration and resolution of this syndrome, now recognized as a highly debilitating condition, there are still no great answers: for this reason it is always important to emphasize that contracting Covid, even in a not serious form, still means exposing oneself to long-term risks that are still not well codified by the scientific community. Guidelines and more tools are expected to best assist these patients.

Official Title
-----------------
Evaluation of the Effects of Treatment With Bioarginin C on Physical Exhaustion , Systemic Inflammatory State and Endothelial Function in Adult Subjects Belonging to the Post-Covid Day Hospital

Conditions
-----------------
Fatigue Syndrome, Chronic, Inflammation

Intervention / Treatment
-----------------
* Dietary Supplement: Bioarginina C


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: subjects with proven positivity to the molecular test for Sars-cov2 with demonstration of microbiological healing patients discharged from FPG or other hospital structures; or only contact in PS; or home management age: range 20-60 years Fatigue operationalized as an affirmative answer to item 7 (CES-D) Exclusion Criteria: Pharmacological therapies with possible interactions with the mechanisms / processes under study (e.g. antihypertensive drugs, cortisone drugs, NSAIDs, immunosuppressants, nitrates)

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Supportive Care
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Bioarginina C<br>vials based on L-arginine and liposomal vitamin C | Dietary Supplement: Bioarginina C<br>* Dietary supplement vials<br>|
| Placebo Comparator: Placebo<br>vials without L-arginine and liposomal vitamin C | Dietary Supplement: Bioarginina C<br>* Dietary supplement vials<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| 6 minute walking test to evaluate Fatigue | Effect of Bioarginina C on the prolonged fatigue | 30 days |